Health News - NAPSTV - Laquinimod

ITʼS ESTIMATED THAT FOUR HUNDRED THOUSAND PEOPLE IN THE U-S SUFFER FROM MULTIPLE SCLEROSIS, OR M-S, THE LEADING CAUSE OF CHRONIC NEUROLOGICAL DISABILITY IN YOUNG ADULTS.
THE MOST COMMON FORM OF M-S IS RELAPSING-REMITTING, WHICH IS CHARACTERIZED BY PARTIAL OR TOTAL RECOVERY AFTER ATTACKS, AND ALL CURRENTLY AVAILABLE THERAPIES INVOLVE INJECTIONS OR INFUSIONS.
LIVING WITH M-S IS REALLY HARD BECAUSE PEOPLE DONT UNDERSTAND THE DISEASE.
ONE OF THE BIGGEST INCONVENIENCES OR DIFFICULTIES IS THE WAY THAT I HAVE TO TAKE THE INJECTIONS.
PHYSICIANS ARE INVESTIGATING A NEW ORAL EXPERIMENTAL DRUG CALLED LAQUINIMOD,
WHICH COULD BE A SIGNIFICANT IMPROVEMENT FOR PATIENTS LIKE ANN WHO CURRENTLY MUST TAKE AN INJECTION OR INFUSION.
LAQUINIMOD IS AN EASY-TO-USE, ONCE-DAILY ORAL INVESTIGATIONAL DRUG CURRENTLY
BEING DEVELOPED FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS.

Category:

Science & Technology

Tags:

• NAPS
• NAPSTV
• MS
• Multiple Schlerosis
• Neurological
• Pharmacuetical
• Laquinimod
• disability
• breaktrhough